JP4480973B2 - Body fat reduction promoter - Google Patents

Body fat reduction promoter Download PDF

Info

Publication number
JP4480973B2
JP4480973B2 JP2003332049A JP2003332049A JP4480973B2 JP 4480973 B2 JP4480973 B2 JP 4480973B2 JP 2003332049 A JP2003332049 A JP 2003332049A JP 2003332049 A JP2003332049 A JP 2003332049A JP 4480973 B2 JP4480973 B2 JP 4480973B2
Authority
JP
Japan
Prior art keywords
lotus
body fat
carnitine
extract
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003332049A
Other languages
Japanese (ja)
Other versions
JP2005097159A (en
Inventor
茂之 山田
愛子 那須
正孝 岸
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Menard Cosmetic Co Ltd
Original Assignee
Nippon Menard Cosmetic Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Menard Cosmetic Co Ltd filed Critical Nippon Menard Cosmetic Co Ltd
Priority to JP2003332049A priority Critical patent/JP4480973B2/en
Publication of JP2005097159A publication Critical patent/JP2005097159A/en
Application granted granted Critical
Publication of JP4480973B2 publication Critical patent/JP4480973B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

本発明は、L−カルニチン及びハス胚芽の抽出物を含有することを特徴とする体脂肪の減少促進剤に関するものである。   The present invention relates to a body fat reduction promoter characterized by containing L-carnitine and a lotus germ extract.

体脂肪は、皮膚の下に蓄積される皮下脂肪及び内臓の周りに蓄積される内臓脂肪をいう。体脂肪の蓄積は、肥満だけでなく、糖尿病、高脂血症、高血圧症などの生活習慣病を引き起こす原因であり、深刻な問題となっている。従って、体脂肪を減少させることは、これらの疾患を予防及び治療する上で大変重要となる。   Body fat refers to subcutaneous fat that accumulates under the skin and visceral fat that accumulates around the viscera. Accumulation of body fat is a cause of not only obesity but also lifestyle-related diseases such as diabetes, hyperlipidemia and hypertension, and is a serious problem. Therefore, reducing body fat is very important in preventing and treating these diseases.

体脂肪を低下させるには、食事制限及び運動が有効とされているが、管理することは極めて難しい。一方、薬物により体脂肪を低下させる方法もあるが、安全性が問題となり、日常的に使用するのは好ましくない。交感神経興奮薬のエフェドリンは心停止の危険があり、食欲を抑制する作用のあるマジンドールやシブトラミンは、頭痛、口渇等の副作用を有する。そこで、日常的に連用可能で安全かつ十分な効果を示す体脂肪の減少促進剤が求められ、各方面で開発が行われてきた。   Dietary restriction and exercise are effective in reducing body fat, but it is extremely difficult to manage. On the other hand, there is a method of reducing body fat with a drug, but safety is a problem and it is not preferable to use it on a daily basis. The sympathomimetic drug ephedrine has a risk of cardiac arrest, and mazindol and sibutramine, which have an effect of suppressing appetite, have side effects such as headache and dry mouth. Therefore, a body fat reduction promoter that can be used on a daily basis and exhibits a safe and sufficient effect has been sought and has been developed in various fields.

例えば、ミカン科植物を有効成分とする脂肪分解促進剤(特許文献1参照)、アザミ族の植物を有効成分とする脂肪分解促進剤(特許文献2参照)、コショウ科植物を有効成分とする脂肪分解促進剤(特許文献3参照)、黄柏エキス及び黄連エキスからなる群から選択される少なくとも1種の成分を有効成分とする脂肪分解促進剤(特許文献4参照)、サンザシの果実成分を有効成分とする脂肪の燃焼を促進させる飲食品(特許文献5参照)、オレンジリーフ、オレンジフラワー、フキタンポポ葉及びカラマスルートの植物を有効成分とする脂肪分解促進剤(特許文献6参照)、構成アシル基中のω3系不飽和アシル基含量が15重量%以上であるジグリセリド及び/又はモノグリセリドを5重量%以上含有する油脂を有効成分とする体脂肪燃焼促進剤(特許文献7参照)などがある。しかし、それらの効果は十分なものではなかった。   For example, a lipolysis promoter containing a citrus plant as an active ingredient (see Patent Document 1), a lipolysis promoter containing a thrips plant as an active ingredient (see Patent Document 2), and a fat containing a pepper plant as an active ingredient Decomposition accelerator (see Patent Document 3), lipolysis accelerator (see Patent Document 4) containing at least one component selected from the group consisting of yellow cocoon extract and yellow continuous extract as an active ingredient, and effective hawthorn fruit component Food / beverage products that promote the burning of fat as ingredients (see Patent Document 5), lipolysis accelerators (see Patent Document 6), which comprise plants of orange leaf, orange flower, dandelion leaves and kalamas root as active ingredients, constituent acyl Body fat containing, as an active ingredient, an oil containing 5% by weight or more of diglyceride and / or monoglyceride having a ω3 unsaturated acyl group content of 15% by weight or more And the like baked accelerator (see patent document 7). However, their effects were not sufficient.

L−カルニチンは、脂肪酸をミトコンドリアに取り込み、エネルギーとする際の必須の物質である。L−カルニチンは脂質代謝に関わる物質であることから、従来より体脂肪を減少させる効果があるといわれてきたが、実際にはその効果は十分なものではない。また、ハス胚芽の抽出物は単独でコラーゲン産生促進効果、皮膚繊維芽細胞増殖促進効果(特許文献8)及び表皮代謝活性化効果(特許文献9)が報告されているが、体脂肪の減少効果については報告されていない。   L-carnitine is an indispensable substance when taking in fatty acids into mitochondria for energy. Since L-carnitine is a substance involved in lipid metabolism, it has hitherto been said to have an effect of reducing body fat, but the effect is not sufficient in practice. In addition, the lotus germ extract alone has been reported to have a collagen production promoting effect, a skin fibroblast proliferation promoting effect (Patent Document 8), and an epidermal metabolism activation effect (Patent Document 9). Has not been reported.

特開平8−81382号公報JP-A-8-81382 特開平8−301780号公報JP-A-8-301780 特開平8−245410号公報JP-A-8-245410 特開平9−95452号公報Japanese Patent Laid-Open No. 9-95452 特開平10−215811号公報JP-A-10-215811 特開平11−228431号公報JP-A-11-228431 特開2001−64672号公報JP 2001-64672 A 特開2002−29980号公報JP 2002-29980 A 特開2002−68993号公報JP 2002-68993 A

このような事情に鑑み、本発明者らはさらに優れた体脂肪の減少促進剤を得るべく鋭意検討を行った結果、L−カルニチン及びハス胚芽の抽出物を組み合わせることが、顕著な体脂肪の減少促進効果を発揮することを見出し、本発明を完成するに至った。   In view of such circumstances, the present inventors have intensively studied to obtain a further excellent body fat reduction promoter, and as a result, combining L-carnitine and lotus germ extract is a significant body fat. The inventors have found that a reduction promoting effect is exhibited, and have completed the present invention.

すなわち、本発明は、L−カルニチン及びハス胚芽の抽出物を含有することを特徴とする体脂肪の減少促進剤である。   That is, the present invention is a body fat reduction promoter characterized by containing L-carnitine and a lotus germ extract.

本発明のL−カルニチンは、体内において必須アミノ酸のリジン及びメチオニンから生合成される他、牛肉、豚肉、羊肉等に含まれており、日常的に摂取されている物質である。また、医薬品においては、塩化物であるL−塩化カルニチンの使用が認められており、安全性の高い成分とされている。本発明での使用にあたっては、化学的或いは酵素的に合成されたもの、微生物により産生されたもの、天然物から得られたもの等を用いることができる。又、L−カルニチンは塩の形であってもよい。L−カルニチンの塩にはナトリウム、カリウム、カルシウム、マグネシウム、亜鉛等の金属塩、アンモニウム、塩酸、硫酸、リン酸、酢酸、プロピオン酸、乳酸、酒石酸、クエン酸、コハク酸、マレイン酸等がある。これらは、単独で又は組み合わせて使用することができる。   The L-carnitine of the present invention is a substance that is not only biosynthesized from the essential amino acids lysine and methionine in the body but also contained in beef, pork, mutton, etc., and is ingested on a daily basis. In pharmaceuticals, the use of L-carnitine chloride, which is a chloride, is recognized and is considered a highly safe component. For use in the present invention, those synthesized chemically or enzymatically, those produced by microorganisms, those obtained from natural products, and the like can be used. L-carnitine may be in the form of a salt. Salts of L-carnitine include metal salts such as sodium, potassium, calcium, magnesium, zinc, ammonium, hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, propionic acid, lactic acid, tartaric acid, citric acid, succinic acid, maleic acid, etc. . These can be used alone or in combination.

本発明のハス胚芽は、平安時代以前からハス胚芽を含むハスの種がいわゆる「ハスの実」として食用されており、極めて安全性の高い食物である。本発明での使用にあたっては、ハス属のハス(Nelumbo nucifera Gaertn.)やキバナハス(N.lutea Pers.)、オニバス属のオニバス(Euyale ferox Salisb.)、オオオニバス属のオオオニバス(Victoria regiaLindl.)等の種の胚芽を使用することができる。生薬として流通するものとしては、蓮芯、蓮子芯、荷梗等が挙げられ、これらを購入して使用することもできる。ハスは、様々な部分が薬用として使われており、それぞれが異なった薬効を有している。例えば、ハス属のハス葉(荷葉)は下痢止め、止血に、果実(蓮肉)と雄しべ(蓮シュ)は強壮に、胚芽(蓮芯、蓮子芯、荷梗)は解熱にと異なった薬効が知られている。また、果実の成分としては多量のデンプンと糖類のラフィノースが知られているのに対し、葉にはロエメリン、ヌシフェリン等のアルカロイドが、そして、胚芽にはメチルコリパリン、ロツシン等の異なるアルカロイドが含まれていることが知られている。   The lotus germ of the present invention is an extremely safe food since the lotus seed containing the lotus germ has been edible as so-called “lotus seed” before the Heian period. For use in the present invention, a lotus of the genus Lotus (Nelumbo nuifera Gaertn.), N. lutea Pers. Seed germs can be used. Examples of products that are distributed as crude drugs include lotus wicks, lotus wicks, and cargo bells. These can be purchased and used. Various parts of lotus are used for medicinal purposes, and each has a different medicinal effect. For example, lotus leaves of lotus genus have anti-diarrhea, hemostasis, fruits (lotus meat) and stamens (lotus) are tonic, and germs (lotus wick, lotus wick, bunko) have different medicinal effects. It has been known. In addition, a large amount of starch and saccharide raffinose are known as fruit components, whereas leaves contain alkaloids such as loemerin and luciferin, and germs contain different alkaloids such as methyl coliparin and rotsin. It is known that

本発明におけるハス胚芽の抽出物は、ハスの種に含まれる胚芽を水もしくはメタノール、エタノール、プロパノール、アセトン等の親水性有機溶媒、又はこれらの混合溶媒で抽出することにより抽出液として得ることができる。又、当該抽出液を濃縮した濃縮液或いは乾燥した粉末の形態でも得ることができる。   The lotus germ extract in the present invention can be obtained as an extract by extracting the germ contained in the lotus seed with water or a hydrophilic organic solvent such as methanol, ethanol, propanol, acetone, or a mixed solvent thereof. it can. It can also be obtained in the form of a concentrated solution obtained by concentrating the extract or a dried powder.

本発明におけるハス胚芽の抽出物及びL−カルニチンの投与量或いは摂取量は、形態、症状、年齢、体重等によって異なるが、L−カルニチンは5〜5000mg/日、好ましくは50〜2000mg/日、より好ましくは100〜1000mg/日、ハス胚芽の抽出物は乾燥ハス胚芽に換算して0.1〜1000mg/日、好ましくは1〜500mg/日、より好ましくは10〜200mg/日である。   The dose or intake of the lotus germ extract and L-carnitine in the present invention varies depending on the form, symptoms, age, weight, etc., but L-carnitine is 5 to 5000 mg / day, preferably 50 to 2000 mg / day, More preferably, it is 100-1000 mg / day, and the lotus germ extract is 0.1-1000 mg / day, preferably 1-500 mg / day, more preferably 10-200 mg / day in terms of dry lotus germ.

本発明の体脂肪の減少促進剤は、医薬品又は食品として用いることができる。医薬品の形態としては、散剤、錠剤、顆粒剤、カプセル剤、トローチ剤、内服液剤、懸濁剤、シロップ剤等が挙げられる。食品の形態としては、上述の医薬品的な形態に加え、ビスケット、クッキー、キャンディー、チョコレート等の菓子、食酢、醤油、ドレッシング等の調味料、ハム、ベーコン、ソーセージ等の食肉製品、かまぼこ、はんぺい等の魚肉練り製品、果汁飲料、清涼飲料、アルコール飲料等の飲料、パン、麺、ジャム等にすることができる。これらの医薬品及び食品は、何れもL−カルニチンを5〜5000mg/日及びハス胚芽の抽出物を乾燥ハス胚芽に換算して0.1mg〜1000mg/日摂取できる形態であるが、摂取量を調整しやすい錠剤、顆粒剤、カプセル剤、トローチ剤、内服液剤及び飲料がより好ましい。又、医薬品及び食品の製造にあたっては、必要に応じて賦形剤、結合剤、滑沢剤、矯味剤、安定剤、ビタミン、ミネラル、香料等の医薬品及び食品の技術分野で通常使用されている補助剤を用いることができる。   The body fat reduction promoter of the present invention can be used as a pharmaceutical or a food. Examples of pharmaceutical forms include powders, tablets, granules, capsules, troches, liquids for internal use, suspensions, syrups and the like. As the form of food, in addition to the above-mentioned pharmaceutical form, confectionery such as biscuits, cookies, candy and chocolate, seasonings such as vinegar, soy sauce and dressing, meat products such as ham, bacon and sausage, kamaboko, rice It can be made into fish paste products such as pies, beverages such as fruit juice beverages, soft drinks, alcoholic beverages, bread, noodles, jams and the like. These medicines and foods can be ingested in an amount of 0.1 to 1000 mg / day in terms of L-carnitine 5 to 5000 mg / day and lotus germ extract converted to dried lotus germ, but the intake is adjusted Tablets, granules, capsules, troches, liquids for internal use, and beverages are more preferable. In the production of pharmaceuticals and foods, they are usually used in the technical fields of pharmaceuticals and foods such as excipients, binders, lubricants, flavoring agents, stabilizers, vitamins, minerals, and fragrances as necessary. Adjuvants can be used.

本発明のL−カルニチン及びハス胚芽の抽出物を含有することを特徴とする体脂肪の減少促進剤には、著しい体脂肪減少効果が認められた。   The body fat reduction promoter characterized by containing the extract of L-carnitine and lotus germ of the present invention has a significant body fat reduction effect.

次に、本発明を実施するための最良の形態として実施例を挙げるが、本発明はこれらに限定されるものではない。なお、実施例に示す(%)は重量(%)を示す。   Next, examples are given as the best mode for carrying out the present invention, but the present invention is not limited to these. In the examples, (%) indicates weight (%).

錠剤
<処方> 配合量(%)
1.L−カルニチン 10.0
2.ハス胚芽の乾燥水抽出物(等量の乾燥ハス胚芽に相当) 1.0
3.カフェイン 1.0
4.還元麦芽糖水飴 85.0
5.ショ糖脂肪酸エステル 3.0
<製造方法>
成分1〜4に70%エタノールを適量加えて練和し、押出し造粒した後に乾燥して顆粒を得る。成分5を加えて打錠成形し、500mgの錠剤を得る。当該錠剤を1日6錠摂取することで、L−カルニチンを300mg/日、乾燥ハス胚芽30mg/日に相当するハス胚芽の抽出物を摂取できる。
Tablet <Prescription> Compounding amount (%)
1. L-carnitine 10.0
2. Lotus water dry water extract (equivalent to an equal amount of dry lotus germ) 1.0
3. Caffeine 1.0
4). Reduced maltose starch syrup 85.0
5). Sucrose fatty acid ester 3.0
<Manufacturing method>
An appropriate amount of 70% ethanol is added to components 1 to 4, kneaded, extruded and granulated, and dried to obtain granules. Ingredient 5 is added and tableted to give 500 mg tablets. By taking 6 tablets per day, an extract of lotus germ corresponding to 300 mg / day of L-carnitine and 30 mg / day of dried lotus germ can be ingested.

トローチ剤
<処方> 配合量(%)
1.L−カルニチン 20.0
2.ハス胚芽の乾燥水抽出物(等量の乾燥ハス胚芽に相当) 5.0
3.乳糖 40.0
4.コーンスターチ 32.0
5.ショ糖脂肪酸エステル 3.0
<製造方法>
成分1〜4に70%エタノールを適量加えて練和して押出し造粒し、乾燥して顆粒を得る。成分5を加えて打錠成形し、1000mgのトローチ剤を得る。当該トローチ剤は、1日3個摂取することで、L−カルニチンを600mg/日、乾燥ハス胚芽150mg/日に相当するハス胚芽の抽出物を摂取できる。
Lozenges <Prescription> Formulation amount (%)
1. L-carnitine 20.0
2. Lotus water dry water extract (equivalent to an equal amount of dried lotus germ) 5.0
3. Lactose 40.0
4). Cornstarch 32.0
5). Sucrose fatty acid ester 3.0
<Manufacturing method>
An appropriate amount of 70% ethanol is added to components 1 to 4, kneaded, extruded and granulated, and dried to obtain granules. Ingredient 5 is added and tableted to obtain 1000 mg of lozenge. By taking 3 lozenges a day, it is possible to take an extract of lotus germ corresponding to 600 mg / day of L-carnitine and 150 mg / day of dried lotus germ.

顆粒剤
<処方> 配合量(%)
1.L−カルニチン 10.0
2.ハス胚芽の乾燥水抽出物(等量の乾燥ハス胚芽に相当) 2.0
3.還元麦芽糖水飴 30.0
4.セルロース 58.0
<製造方法>
成分1〜4に70%エタノールを適量加えて練和して押出し造粒し、乾燥して顆粒剤を得る。当該顆粒剤は、1回2000mgずつ1日3回摂取することで、L−カルニチンを600mg/日、乾燥ハス胚芽120mg/日に相当するハス胚芽の抽出物を摂取できる。
Granules <Prescription> Compounding amount (%)
1. L-carnitine 10.0
2. Lotus water dry water extract (equivalent to an equal amount of dried lotus germ) 2.0
3. Reduced maltose starch syrup 30.0
4). Cellulose 58.0
<Manufacturing method>
An appropriate amount of 70% ethanol is added to components 1 to 4, kneaded, extruded and granulated, and dried to obtain granules. The granule can ingest an extract of lotus germ corresponding to 600 mg / day of L-carnitine and 120 mg / day of dried lotus germ by ingesting 2000 mg at a time three times a day.

カプセル剤
<処方> 配合量(%)
1.L−カルニチン 10.0
2.ハス胚芽の乾燥エタノール抽出物(5倍量の乾燥ハス胚芽に相当) 2.0
3.コエンザイムQ10 0.2
4.セルロース 87.8
<製造方法>
成分1〜4を混合し、2号硬カプセルに250mg充填してカプセル剤を得る。当該カプセル剤は、1日6カプセル摂取することで、L−カルニチンを150mg/日、乾燥ハス胚芽150mg/日に相当するハス胚芽の抽出物を摂取できる。
Capsule <Prescription> Content (%)
1. L-carnitine 10.0
2. Lotus ethanol extract of dried lotus germ (equivalent to 5 times the amount of dried lotus germ) 2.0
3. Coenzyme Q10 0.2
4). Cellulose 87.8
<Manufacturing method>
Ingredients 1-4 are mixed and 250 mg is filled into No. 2 hard capsule to obtain a capsule. By taking 6 capsules per day, the capsule can take in an extract of lotus germ corresponding to 150 mg / day of L-carnitine and 150 mg / day of dried lotus germ.

飲料
<処方> 配合量(%)
1.L−カルニチン 1.0
2.ハス胚芽の30%エタノール抽出液(等量の乾燥ハス胚芽に相当) 0.5
3.10%コエンザイムQ10水溶液製剤 1.0
4.カフェイン 0.1
5.ショ糖 6.0
6.クエン酸 0.7
7.香料 適量
8.精製水で全量を100とする。
<製造方法>
成分8に成分1〜7を加え、撹拌溶解して濾過し、加熱殺菌して30mLガラス瓶に充填する。当該飲料は、1日1本摂取することでL−カルニチンを300mg/日、乾燥ハス胚芽150mg/日に相当するハス胚芽の抽出物を摂取できる。
Beverage <Prescription> Blending amount (%)
1. L-carnitine 1.0
2. 30% ethanol extract of lotus germ (equivalent to equivalent amount of dried lotus germ) 0.5
3. 10% Coenzyme Q10 aqueous solution formulation 1.0
4). Caffeine 0.1
5). Sucrose 6.0
6). Citric acid 0.7
7). Perfume appropriate amount 8. Bring the total amount to 100 with purified water.
<Manufacturing method>
Add ingredients 1-7 to ingredient 8, dissolve with stirring, filter, heat sterilize and fill into a 30 mL glass bottle. The beverage can ingest an extract of lotus germ corresponding to 300 mg / day of L-carnitine and 150 mg / day of dried lotus germ by ingesting once a day.

比較例
飲料
配合量(%)
<処方> 比較例1 比較例2 比較例3
1.L−カルニチン 0.0 1.0 0.0
2.ハス胚芽の30%エタノール抽出液 0.0 0.0 0.5
(等量の乾燥ハス胚芽に相当)
3.10%コエンザイムQ10水溶液製剤 1.0 1.0 1.0
4.カフェイン 0.1 0.1 0.1
5.ショ糖 6.0 6.0 6.0
6.クエン酸 0.7 0.7 0.7
7.香料 適量 適量 適量
8.精製水で全量を100とする。
<製造方法>
成分8に成分1〜7を加え、撹拌溶解して濾過し、加熱殺菌して30mLガラス瓶に充填する。
Comparative example Beverage
Compounding amount (%)
<Prescription> Comparative Example 1 Comparative Example 2 Comparative Example 3
1. L-carnitine 0.0 1.0 0.0
2. 30% ethanol extract of lotus germ 0.0 0.0 0.5
(Equivalent amount of dried lotus germ)
3. 10% Coenzyme Q10 aqueous solution formulation 1.0 1.0 1.0
4). Caffeine 0.1 0.1 0.1
5). Sucrose 6.0 6.0 6.0
6). Citric acid 0.7 0.7 0.7
7). Perfume appropriate amount appropriate amount appropriate amount Bring the total amount to 100 with purified water.
<Manufacturing method>
Add ingredients 1-7 to ingredient 8, dissolve with stirring, filter, heat sterilize and fill into a 30 mL glass bottle.

10週齢のWistar系雄性ラットを各群8匹ずつ4群に分け、表1記載の組成の食餌を2週間与えた。体脂肪率は小動物用体脂肪測定装置(EM−SCAN SA−2 セントラル科学貿易)で測定した。得られた結果を表2に示す。   Ten 10-week-old Wistar male rats were divided into 4 groups of 8 rats in each group, and a diet having the composition shown in Table 1 was given for 2 weeks. The body fat percentage was measured with a body fat measuring apparatus for small animals (EM-SCAN SA-2 Central Science Trade). The obtained results are shown in Table 2.

Figure 0004480973
Figure 0004480973

Figure 0004480973
Figure 0004480973

表2の結果より、L-カルニチン及びハス胚芽の抽出物を含まない食餌を与えた試験群1と比較して、L−カルニチンを含む食餌の試験群2及びハス胚芽の抽出物を含む食餌の試験群3における体脂肪率の減少はわずかである。一方、L−カルニチン及びハス胚芽の抽出物を含む食餌を与えた試験群4は、著しく体脂肪が低下していることがわかる。   From the results of Table 2, it can be seen that the test group 2 of the diet containing L-carnitine and the diet containing the extract of the lotus germ were compared with the test group 1 given the diet not containing the extract of L-carnitine and the lotus germ. The decrease in body fat percentage in test group 3 is slight. On the other hand, it can be seen that the test group 4 fed the diet containing the extract of L-carnitine and the lotus germ significantly reduced body fat.

25〜40歳の健常男性3名及び女性2名(A、B、C、D、E)に、食生活を変えることなく、実施例5の飲料を1日1本8週間摂取させ、BMI〔Body Mass Index:体重kg/(身長m×身長m)〕、体脂肪率、ウエストサイズを測定した。結果を表4に示す。   Three healthy men aged 25 to 40 and two women (A, B, C, D, E) were allowed to consume the beverage of Example 5 once a day for 8 weeks without changing their diet, and BMI [ Body Mass Index: body weight kg / (height m × height m)], body fat percentage, and waist size were measured. The results are shown in Table 4.

Figure 0004480973
Figure 0004480973

表3の結果より、本発明の体脂肪の減少促進剤を摂取すると、食生活を変えることなく、体脂肪率が減少し、それに伴いBMI、ウエストサイズが低下していることがわかる。   From the results in Table 3, it can be seen that when the body fat reduction promoter of the present invention is ingested, the body fat percentage decreases without changing the diet, and accordingly, BMI and waist size decrease.

L−カルニチン及びハス胚芽の抽出物を含有する体脂肪の減少促進剤は、過度の体脂肪が起因となる生活習慣病の予防及び治療にも適用できる。

The body fat reduction promoter containing L-carnitine and lotus germ extract can also be applied to the prevention and treatment of lifestyle-related diseases caused by excessive body fat.

Claims (2)

L−カルニチン及びハス胚芽の抽出物を含有することを特徴とする体脂肪の減少促進剤。 A body fat reduction promoter comprising L-carnitine and a lotus germ extract. L−カルニチンを5〜5000mg/日及びハス胚芽の抽出物を乾燥ハス胚芽に換算して0.1〜1000mg/日摂取できる形態である請求項1記載の体脂肪の減少促進剤。
The body fat reduction promoter according to claim 1, wherein L-carnitine is in a form that can be ingested in an amount of 5-5000 mg / day and a lotus germ extract converted to dried lotus germ in an amount of 0.1-1000 mg / day.
JP2003332049A 2003-09-24 2003-09-24 Body fat reduction promoter Expired - Lifetime JP4480973B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003332049A JP4480973B2 (en) 2003-09-24 2003-09-24 Body fat reduction promoter

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003332049A JP4480973B2 (en) 2003-09-24 2003-09-24 Body fat reduction promoter

Publications (2)

Publication Number Publication Date
JP2005097159A JP2005097159A (en) 2005-04-14
JP4480973B2 true JP4480973B2 (en) 2010-06-16

Family

ID=34460517

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003332049A Expired - Lifetime JP4480973B2 (en) 2003-09-24 2003-09-24 Body fat reduction promoter

Country Status (1)

Country Link
JP (1) JP4480973B2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0606864D0 (en) * 2006-04-05 2006-05-17 Univ Nottingham Increades fatty acid oxidation
JP5819209B2 (en) * 2012-01-24 2015-11-18 日本メナード化粧品株式会社 Differentiation promoter from stem cells to brown adipocytes
JP2018100247A (en) * 2016-12-21 2018-06-28 松浦薬業株式会社 Dextrin formulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11310531A (en) * 1998-04-28 1999-11-09 Asahi Breweries Ltd Fat decomposition promoter with higenamine as active ingredient

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11310531A (en) * 1998-04-28 1999-11-09 Asahi Breweries Ltd Fat decomposition promoter with higenamine as active ingredient

Also Published As

Publication number Publication date
JP2005097159A (en) 2005-04-14

Similar Documents

Publication Publication Date Title
JP2010202520A (en) Skin improver and oral composition for cosmetic and health purposes
WO2002055074A1 (en) Preventives or remedies for arthritis
KR20140021598A (en) Composition, glucose metabolism-improving agent, and method for improving glucose metabolism
JP5066670B2 (en) Anti-obesity agent and edible composition
JP5053535B2 (en) Oral for improving sleep or waking up
JP5749880B2 (en) Body fat accumulation improving agent and metabolic syndrome improving agent comprising D-tagatose as an active ingredient
JP6222663B2 (en) Muscle atrophy inhibitor
WO2015137387A1 (en) Muscle enhancing drug
JP2008143811A (en) Lipid metabolism promoting composition
JP4480973B2 (en) Body fat reduction promoter
JP5710091B2 (en) NO production promoter
JP2009155334A (en) Medicine
JP2007099653A (en) Arthrodynia ameliorator
JP2009107987A (en) Muscle enhancer
JP6143294B2 (en) Muscle glycogen accumulation promoter during muscle glycogen recovery, food and drink for muscle glycogen accumulation promotion during muscle glycogen recovery, and method for producing muscle glycogen accumulation promoter during muscle glycogen recovery
KR101782132B1 (en) Health care food of composition comprising the extract material in Ginkgo biloba and Plantago ovata
JP4915959B2 (en) Novel sweetener with sugar-like taste, production method and use thereof
JP2003286180A (en) Obesity inhibitor and food containing the same
US20070093554A1 (en) Agent for improving feeling of cold
KR102245628B1 (en) Composition for internal use
JP2013124222A (en) Visceral fat reducing agent
JPH069419A (en) Method for improving taste of essence of pine and oral ingesta obtained by the same method
KR20120040890A (en) Blueberry fermentation extract as an effective components for prevention and treatment of obesity
JP2003012527A (en) Hyperphagia inhibitor
JP2006137730A (en) Anti-fatigue agent or stamina enhancing agent, functional food or cosmetic

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100105

TRDD Decision of grant or rejection written
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100215

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100316

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100317

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130326

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4480973

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140326

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term